Qlife Holding AB has carried out a private placement of approximately SEK 90 million through a directed issue of 2,132,271 shares at a subscription price of SEK 42 per share.
Qlife Holding is a medical device company focused on clinical biomarker testing of whole blood. The company’s products enables testing at home instead of in the lab, which facilitates easy access to blood sample results and in turn facilitates increased monitoring of parameters that enable care improvement. Qlife Holding has its headquarters in Helsingborg and is listed on Nasdaq First North Growth Market.
The private placement was directed mainly to strategic and institutional investors and the subscription price was determined based on a market sounding before the new issue and negotiation and agreement with the investors entitled to subscribe. The issue proceeds of approximately SEK 90 million will be used to fund a dramatic upscaling of production capacity and research and development, which includes investments in new tests and regulatory work to approve new tests.
Setterwalls has acted as legal advisor to Qlife Holding in connection with the private placement.